BNP Paribas Financial Markets’s Adicet Bio ACET Stock Holding History

BNP Paribas Financial Markets’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$432	Hold	50	–	–	﹤0.01%	5694
2026 Q1	$340	Hold	50	–	–	﹤0.01%	5577
2025 Q4	$421	Sell	50 -6	-11%	-$66	﹤0.01%	5494
2025 Q3	$726	Hold	56	–	–	﹤0.01%	5270
2025 Q2	$547	Hold	56	–	–	﹤0.01%	5214
2025 Q1	$675	Hold	56	–	–	﹤0.01%	5110
2024 Q4	$860	Buy	+56	New	+$1.06K	﹤0.01%	5106
2020 Q3	–	Sell	-543	Closed	-$131K	–	4209
2020 Q2	$131K	Buy	543 +501	+1,193%	+$98.4K	﹤0.01%	2661
2020 Q1	$4.89K	Buy	42 +26	+163%	+$3.86K	﹤0.01%	4081
2019 Q4	$2.66K	Buy	16 +1	+7%	+$506	﹤0.01%	4207
2019 Q3	$15.1K	Buy	15 +6	+67%	+$6.7K	﹤0.01%	4059
2019 Q2	$9.96K	Sell	9 -6	-40%	-$5.44K	﹤0.01%	4102
2019 Q1	$11.7K	Buy	15 +14	+1,400%	+$12.7K	﹤0.01%	4009
2018 Q4	$793	Sell	1 -1	-50%	-$1.32K	﹤0.01%	3951
2018 Q3	$3.15K	Hold	2	–	–	﹤0.01%	4193
2018 Q2	$1.9K	Sell	2 -8	-80%	-$8.61K	﹤0.01%	4259
2018 Q1	$10.2K	Buy	+10	New	+$18.3K	﹤0.01%	4012

Other funds holding ACET

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

BNP Paribas Financial Markets's ACET Position: Q2 2026 in Review

BNP Paribas Financial Markets held its Adicet Bio (ACET) position steady in Q2 2026 at 50 shares worth $432. The position accounts for ﹤0.01% of the portfolio, ranked #5694.

BNP Paribas Financial Markets first reported a position in ACET in Q1 2018 and has held it in 17 quarters since. The position peaked at $131K in Q2 2020. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

BNP Paribas Financial Markets held 50 shares of Adicet Bio worth $432 as of Q2 2026.
BNP Paribas Financial Markets left its Adicet Bio share count unchanged in Q2 2026.
Adicet Bio made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5694 holding.
BNP Paribas Financial Markets first reported a position in Adicet Bio in Q1 2018 and has held it in 17 quarters since.
BNP Paribas Financial Markets's Adicet Bio position peaked at $131K in Q2 2020.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.